Advance Search
ZHANG Farong. Efficacy of rituximab orbital injection combined with intravenous drip of methylprednisolone in treating Graves' ophthalmopathy and its influence on immune system[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 11-15, 22. DOI: 10.7619/jcmp.20244709
Citation: ZHANG Farong. Efficacy of rituximab orbital injection combined with intravenous drip of methylprednisolone in treating Graves' ophthalmopathy and its influence on immune system[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 11-15, 22. DOI: 10.7619/jcmp.20244709
shu

Efficacy of rituximab orbital injection combined with intravenous drip of methylprednisolone in treating Graves' ophthalmopathy and its influence on immune system

  • Department of Endocrinology, Ziyang City People's Hospital in Sichuan Province, Ziyang, Sichuan, 641300

More Information
  • Received Date: October 09, 2024
  • Revised Date: December 18, 2024
    Graphical Abstract
    • Abstract
  • Objective 

    To explore the efficacy of rituximab (RTX) orbital injection combined with intravenous drip of methylprednisolone in treating Graves' ophthalmopathy.

    Methods 

    A total of 102 patients with Graves' ophthalmopathy in the Ziyang City People's Hospital from July 2021 to January 2023 were randomly divided into combination group (n=34), methylprednisolone group (n=34), and RTX group (n=34). The methylprednisolone group was given glucocorticoids (methylprednisolone) monotherapy, the RTX group was given RTX monotherapy, and the combination group was given RTX combined with methylprednisolone. The total effective rate, ophthalmic manifestations, thyroid volume, thyroid immune antibodies [thyroid globulin antibody (TGAb), thyrotropin receptor antibody (TRAb) and thyroid peroxidase antibody (TPOAb) levels], the Clinical Activity Scale (CAS), levels of immunoglobulins in peripheral blood [immunoglobulin G4 (IgG4) and IgG4/IgG], and adverse reactions were compared among the three groups.

    Results 

    The total effective rate was 97.06%(33/34) in the combination group, which was significantly higher than 79.41%(27/34) in the methylprednisolone group and 76.47%(26/34) in the RTX group (P < 0.05). After 4 and 8 weeks of treatment, the exophthalmos degree, interocular distance, intraocular pressure, and retrobulbar soft tissue volume in the combination group were significantly lower than those in the methylprednisolone group and the RTX group (P < 0.05); the thyroid volume and the CAS score in the combination group were significantly lower than those in the methylprednisolone group and the RTX group (P < 0.05); the TGAb, TRAb and TPOAb levels in the combination group were significantly lower than those in the methylprednisolone group and the RTX group (P < 0.05); the IgG4 and IgG4/IgG in the combination group were significantly lower than those in the methylprednisolone group and the RTX group (P < 0.05). There was no significant difference in the incidence of adverse

    Conclusions 

    For patients with Graves' ophthalmopathy, therapeutic effect of RTX orbital injection combined with intravenous drip of methylprednisolone is better, which is beneficial for improving ophthalmic manifestations and regulating levels of TGAb, TRAb, TPOAb and immunoglobulins.

    • FullText(HTML)
    • References (26)
  • [1]
    BARTALENA L, TANDA M L. Current concepts regarding Graves' orbitopathy[J]. J Intern Med, 2022, 292(5): 692-716. doi: 10.1111/joim.1352407.031
    [2]
    ANTONELLI A, FALLAHI P, ELIA G, et al. Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(1): 101388. doi: 10.1016/j.beem.2020.101388
    [3]
    曹业迪, 高莹. 胰岛素样生长因子Ⅰ受体抑制剂通过改变甲状腺相关眼病中成纤维细胞的免疫表型发挥治疗作用[J]. 中华医学杂志, 2022, 102(6): 398.
    [4]
    GONZÁLEZ-GARCÍA A, SALES-SANZ M. Treatment of Graves' ophthalmopathy[J]. Med Clin, 2021, 156(4): 180-186. doi: 10.1016/j.medcli.2020.07.031
    [5]
    HALL A J H, TOPLISS D J. Medical and surgical treatment of thyroid eye disease[J]. Intern Med J, 2022, 52(1): 14-20. doi: 10.1111/imj.15067
    [6]
    余进海, 戴德泉, 张萍, 等. 利妥昔单抗对中重度甲状腺相关眼病疗效的Meta分析[J]. 国际眼科杂志, 2020, 20(8): 1379-1383.
    [7]
    CHEN J, CHEN G, SUN H L. Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis[J]. Hormones, 2021, 20(2): 279-286. doi: 10.1007/s42000-021-00282-6
    [8]
    曾鹏, 余韵, 范淑贤, 等. 甲状腺相关眼病的EUGOGO临床分级特征[J]. 中山大学学报: 医学版, 2018, 39(6): 884-890.
    [9]
    布阿提卡木·阿布都克日木, 李琴, 王宁荐, 等. 甲强龙静脉冲击治疗Graves眼病对免疫球蛋白及CD系列的影响[J]. 中华内分泌代谢杂志, 2019, 35(9): 756-760.
    [10]
    肖许甲, 税宇萍, 冯先琼. 甲状腺相关眼病患者眼征与生活质量的关系[J]. 国际眼科杂志, 2022, 22(12): 2099-2104. doi: 10.3980/j.issn.1672-5123.2022.12.33
    [11]
    MITKA K, SOKOŁOWSKI G, PACH D, et al. Graves' disease and exophthalmos-a mask for meningioma[J]. Endokrynol Pol, 2021, 72(2): 179-180. doi: 10.5603/EP.a2021.0006
    [12]
    KIM M, CHANG J H, LEE N K. Quantitative analysis of extraocular muscle volume and exophthalmos reduction after radiation therapy to treat Graves' ophthalmopathy: a pilot study[J]. Eur J Ophthalmol, 2021, 31(2): 340-345. doi: 10.1177/1120672119873841
    [13]
    梁健, 张振, 曾怡. 糖皮质激素冲击治疗对活动期中重度甲状腺相关眼病患者的疗效及影响因素分析[J]. 河北医学, 2023, 29(5): 752-756.
    [14]
    WANG Y, WANG H, LI L H, et al. Novel observational study protocol to develop a prediction model that identifies patients with Graves' ophthalmopathy insensitive to intravenous glucocorticoids pulse therapy[J]. BMJ Open, 2021, 11(12): e053173.
    [15]
    AHN H Y, LEE J K. Intravenous glucocorticoid treatment for Korean Graves' ophthalmopathy patients[J]. J Korean Med Sci, 2020, 35(23): e177.
    [16]
    DE KEIZER B, LABAN K G, KALMANN R. Zirconium-89 labelled rituximab PET-CT imaging of Graves' orbitopathy[J]. Eur J Nucl Med Mol Imaging, 2020, 47(3): 738-739.
    [17]
    王萍, 张少波, 张琼, 等. 利妥昔单克隆抗体局部注射联合甲基强地松龙治疗甲状腺相关性眼病的临床疗效分析[J]. 临床眼科杂志, 2020, 28(2): 155-158.
    [18]
    KANG S, HAMED AZZAM S, MINAKARAN N, et al. Rituximab for thyroid-associated ophthalmopathy[J]. Cochrane Database Syst Rev, 2022, 6(6): CD009226.
    [19]
    何志伟, 刘洲君, 胡欣, 等. 利妥昔单抗单药或联合糖皮质激素治疗Graves眼病的有效性和安全性研究[J]. 中华内分泌代谢杂志, 2022, 38(8): 633-638.
    [20]
    BISCARINI F, MASETTI G, MULLER I, et al. Gut microbiome associated with Graves disease and Graves orbitopathy: the INDIGO multicenter European study[J]. J Clin Endocrinol Metab, 2023, 108(8): 2065-2077.
    [21]
    KYRIAKOS G, PATSOURAS A, VOUTYRITSA E, et al. The role of TPOAb in thyroid-associated orbitopathy: a systematic review[J]. Ocul Immunol Inflamm, 2022, 30(7/8): 1740-1746.
    [22]
    KATAHIRA M, TSUNEKAWA T, MIZOGUCHI A, et al. Clinical significance of thyroglobulin antibodies and thyroid peroxidase antibodies in Graves' disease: a cross-sectional study[J]. Hormones, 2023, 22(2): 253-261.
    [23]
    肖毅, 林发全, 刘奕, 等. 血清抗甲状腺球蛋白抗体在Graves病患者中表达水平及临床意义[J]. 广西医科大学学报, 2023, 40(4): 638-644.
    [24]
    ZAWADZKA-STARCZEWSKA K, STASIAK B, WOJCIECHOWSKA-DURCZYNSKA K, et al. Novel insight into non-genetic risk factors of Graves' orbitopathy[J]. Int J Environ Res Public Health, 2022, 19(24): 16941.
    [25]
    张雯, 王嫄, 王晟宇, 等. 外周血IgG4、IgG及IgG4/IgG比值与Graves眼病严重程度、甲状腺免疫抗体的相关性分析[J]. 解放军医药杂志, 2021, 33(10): 74-76, 96.
    [26]
    张海桃, 陈欢欢. 血清IgG4与甲状腺相关性眼病的研究进展[J]. 南京医科大学学报: 自然科学版, 2022, 42(9): 1335-1340.
    • Related Articles

Catalog

    Get Citation
    PDF
    XML
    Article views (24) PDF downloads (4) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References

    © 2020 《实用临床医药杂志》编辑部

    Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    Supported by: Beijing Renhe Information Technology Co., Ltd.   Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return